{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:09:55Z","timestamp":1790125795863,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2022HXFH013"],"award-info":[{"award-number":["2022HXFH013"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC1691"],"award-info":[{"award-number":["2024NSFSC1691"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jve.2026.100629","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:10:19Z","timestamp":1781208619000},"page":"100629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Maintaining versus switching antiviral therapy in chronic hepatitis B patients with low-level viremia"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3415-8397","authenticated-orcid":false,"given":"Yongyong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengrun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzammal","family":"Sahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoyou","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jve.2026.100629_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ID9.0000000000000128","article-title":"Diagnosis, care and treatment for people with chronic hepatitis B infection (text extract): executive summary","volume":"4","year":"2024","journal-title":"Infect Dis Immun"},{"issue":"10","key":"10.1016\/j.jve.2026.100629_bib2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, Cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jve.2026.100629_bib3","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"10.1016\/j.jve.2026.100629_bib4","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","article-title":"AASLD ISDA practice guideline on treatment of chronic hepatitis B","volume":"83","author":"Ghany","year":"2026","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jve.2026.100629_bib5","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jve.2026.100629_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29213","article-title":"Higher HBeAg-reversion virological relapse and lower sustained remission after treatment cessation in tenofovir-treated HBeAg-positive patients","volume":"95","author":"Chen","year":"2023","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.jve.2026.100629_bib7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jve.2026.100629_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3350\/cmh.2017.0005","article-title":"Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: real-Life experience","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.jve.2026.100629_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jve.2026.100629_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1016\/j.jve.2026.100629_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jvh.14032","article-title":"Updated guidelines for the prevention and management of chronic hepatitis B-World health organization 2024 compared with China 2022 HBV guidelines","volume":"31","author":"Wong","year":"2024","journal-title":"J Viral Hepat"},{"issue":"23","key":"10.1016\/j.jve.2026.100629_bib12","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1097\/CM9.0000000000001793","article-title":"Low-level viremia in nucleoside analog-treated chronic hepatitis B patients","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin Med J (Engl Ed)"},{"issue":"6","key":"10.1016\/j.jve.2026.100629_bib13","first-page":"850","article-title":"Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease","volume":"9","author":"Zhang","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"12","key":"10.1016\/j.jve.2026.100629_bib14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/jvh.14012","article-title":"Multiple low-level viraemia suggest hindered liver fibrosis regression in chronic hepatitis B patients during antiviral therapy","volume":"31","author":"Lu","year":"2024","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jve.2026.100629_bib15","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.2147\/IDR.S463843","article-title":"Non-invasive monitoring of the impact of low-level viremia on liver fibrosis in treated chronic hepatitis B patients","volume":"17","author":"Xu","year":"2024","journal-title":"Infect Drug Resist"},{"issue":"3","key":"10.1016\/j.jve.2026.100629_bib16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3350\/cmh.2020.0012","article-title":"Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jve.2026.100629_bib17","article-title":"Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment","volume":"14","author":"Li","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.jve.2026.100629_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12985-025-02981-7","article-title":"Predictors of low-level viremia in chronic hepatitis B and the efficacy of pegylated interferon-alpha: a real-world study","volume":"22","author":"Zhang","year":"2025","journal-title":"Virol J"},{"issue":"1","key":"10.1016\/j.jve.2026.100629_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.livres.2022.02.001","article-title":"Risk factors for very low-level viremia in patients with chronic hepatitis B virus infection: a single-center retrospective study","volume":"6","author":"Lu","year":"2022","journal-title":"Liver Res"},{"issue":"1","key":"10.1016\/j.jve.2026.100629_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5152\/tjg.2023.21978","article-title":"Prevalence and associated factors of low-level viremia in chronic hepatitis B patients after long-term therapy with nucleos(t)ide analogs","volume":"34","author":"Han","year":"2023","journal-title":"Turk J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jve.2026.100629_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01827-24","article-title":"Efficacy and safety of switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low-level viremia: a real-world 48-week extension study","volume":"69","author":"He","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jve.2026.100629_bib22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/liv.14786","article-title":"Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia","volume":"41","author":"Li","year":"2021","journal-title":"Liver Int"}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664026000099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664026000099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:27:08Z","timestamp":1789212428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664026000099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2055664026000099"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2026.100629","relation":{},"ISSN":["2055-6640"],"issn-type":[{"value":"2055-6640","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintaining versus switching antiviral therapy in chronic hepatitis B patients with low-level viremia","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2026.100629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100629"}}